Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Lopes De Jesus, Carlos ^a   Atallah, A N ^b   Valente, O ^b   Moca Trevisani V F ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; FREE RADICAL; PLACEBO; SUPEROXIDE DISMUTASE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG COST; DRUG EFFECT; HUMAN; LASER COAGULATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 44949149146     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006695.pub2     Document Type: Review

References (51)

1. Bandello 2003 Bandello F, Pognuz R, Polito A, Pirracchio A, Menchini F, Ambesi M. Diabetic macular edema: classification, medical and laser therapy. Seminars in Ophthalmology 2003;18:251-58.
2. Caldwell 2005 Caldwell RB, Bartoli M, Behzadian MA, El Remessy AE, Al Shabrawey M, Platt DH, et al.Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Current drug targets 2005;6:511-24.
3. Comer 2004 Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy [erratuam appears in Curr Opin Ophthalmol 2005 Jun; 16(3): 195]. Current opinion in ophthalmology 2004;15:508-18.
4. Comer 2005 Comer GM, Ciulla TA. Current and future pharmacological intervention for diabetic retinopathy. Expert Opinion on Emerging Drugs 2005;10:441-55.
5. Cunha-Vaz 1979 Cunha-Vaz JG, Faria DA, Jr, Fonseca JR. Studies on diabetic retinopathy. III. Management. Experientia Ophthalmologica 1979;5:9-16.
6. Cunha-Vaz 2004 Cunha-Vaz JG. Medical treatment of retinopathy of type2-diabetes. Ophthalmologica 2004;218:291-96.
7. De La Cruz 2004 De La Cruz JP, Gonzalez-Correa JA, Guerrero A, De la Cuesta FS, et al.Pharmacological approach to diabetic retinopathy. Diabetes/metabolism research and reviews 2004;20:91-113.
8. Gaede 2006 Gaede PH. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: rationale and effect on late daibetic complications. Danish Medical Bulletin 2006;53:258-84.
9. Gupta 2005 Gupta MM, Chari S, Gupta MM, Chari S. Lipid peroxidation and antioxidant status in patients with diabetic retinopathy. Indian journal of physiology and pharmacology 2005;49:187-92.
10. Ivanisevic 1994 Ivanisevic M. Present approach to medical therapy of diabetic retinopathy. Acta Clinica Croatica 1944;33:221-7.
11. Jennings 1987 Jennings PE, Chirico S, Jones AF, Lunec J, Barnett AH, et al.Vitamin C metabolities and microangiopathy in diabetes mellitus. Diabetes research 1987;6:151-4.
12. Juhl 2004 Juhl B. Vitamin C treatment reduces transcapillary escape rate of albumin in type 1 diabetes. European Journal of Internal Medicine 2004;15:428-35.
13. Kowluru 2001 Kowluru RA, Kennedy A. Therapeutical potential of anti-oxidants and diabetic retinopathy. Expert opinion on investigational drugs 2001;10:1665-76.
14. Leal 2005 Leal EC, Santiago AR, Ambrosio AF. Old and new drug targets indiabetic retinopathy: from biochemical changes to inflammation and neurodegeneration. Current drug targets. CNS and neurological disorders 2005;4:421-34.
15. Mamputu 2004 Mamputu JC, Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effects of antioxidants. Journal of Leukocyte Biology 2004;75:1062-9.
16. Mayer-Davis1998 Mayer-Davis EJ, Bell RA, Reboussin BA, Rushing J, Marshall JA, Hamman RF. Antioxidant nutrient intake and diabetic retinopathy: The San Luis Valley Diabetes Study.Ophthalmology 1998;105:2264-70.
17. Millen 2003 Millen AE, Gruber M, Klein R, Klein BEK, Palta M, Mares JA. Relations of serumascorbic acid and a-tocopherol to diabetic retinopathy in the Third National Health and Nutrition Examination Survey. American Journal of Epidemiology 2003;158:225-233.
18. Newport 2005 Newport A, Lockwood B. Use of nutraceuticals for eye health. Pharmaceutical Journal 2005;275:261-4.
19. Palmieri 2006 Palmieri B, Sblendorio V. Oxidative stress detection: what for? Part I. European Review for Medical & Pharmacological Sciences 2006;10:291-317.
20. Porta 2004 Porta M, Allione A. Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacology & Therapeutics 2004;103:167-77.
21. Rema 1995 Rema M, Mohan V, Bhaskar A, Shanmugasundaram KR, et al.Does antioxidant stress play a role in diabetic retinopathy?. Indian journal of ophthalmology 1995;43:17-21.
22. Sinclair 1992 Sinclair AJ, Girling AJ, Gray L, Lunec J, Barnett AH, et al.An investigation of the relationship between free radical activity and vitamin C metabolism in olderly diabetic subjects with retinopathy. Gerontology 1992;38:268-74.
23. Soro-Paavonen 2006 Soro-Paavonen A, Forbes JM. Novel therapeutics for diabetic micro-and macrovascular complications. Current Medicinal Chemistry 2006;13:1777-88.
24. Vinson 1994 Vinson J, Hsu C, Possanza C, Drack A, Pane D, Davis R, et al.Lipid peroxidation and diabetic complications: effect of antioxidant vitamins C and E. Advances in experimental medicine and biology 1944;366:430-2.
25. Wang 2005 Wang X-F. Therapeutic methods of diabetic retinopathy and its molecular biological study. Zhongguo Lingchuan Kangfu 2005;9:136-8.
26. Wegewitz 2005 Wegewitz U, Gohring I, Spranger J. Novel approaches in the treatment of angiogenic eye disease. Current Pharmaceutical Design 2005;11:2311-30.
27. Yam 2007 Yam JC, Kwok AK, Yam JCS, Kwok AKH. Update on the treatment of diabetic retinopathy. Hong Kong medical journal 2007;13:46-60.
28. Yildirim 2007 Yildrim Z, Ucgun NI, Kilic N, Gursel E, Sepici-Dincel A, et al.Antioxidant enzymes and diabetic retinopathy. Annals of the New York Academy of Sciences 2007;1100:199-206.
29. ADA 1997 American Diabetes Association. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20 Suppl 1:S5-20.
30. ADA 1999 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22 Suppl 1:S5-19.
31. Balasubramanyam 2002 Balasubramanyam M, Rema M, Premanand C. Biochemical and molecular mechanisms of diabetic retinopathy. Current Science 2002;83:1506-14.
32. Balasubramanyam 2003 Balasubramanyam M, Rema M, Premanand C. Biochemical and molecular mechanisms of diabetic retinopathy. Current Science 2003;83:1506-14.
33. Carr 1999 Carr A C, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. American Journal of Clinical Nutrition 1999;6:1086-107.
34. Cohen 1960 Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
35. Evans 1995 Evans PJ. Metal ion release from mechanically-disrupted human arterial wall. Implications for the development of atherosclerosis. Free Radicals Residence 1995;23:465.
36. Fong 2003 Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al.Diabetic retinopathy. Diabetes Care 2003;26:99-102.
37. Fridovich 1995 Fridovich I. Superoxide radical and superoxide dismutases. Annual Review of Biochemistry 1995;64:97.
38. Halliwell 1999 Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Third Edition. Oxford: Oxford University Press, 1999:23; 106-7.
39. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002;21:1539-58.
40. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
41. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons Ltd.
42. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
43. Klein 1984 Klein R, Klein BE, Mors SE, Davis MD, De Mets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Archives of Ophthalmology 1984;102(4):532-52.
44. Lau 2006 Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
45. Moher 1999 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896-900.
46. Nishikimi 1996 Nishikimi M, Yagi K. Biochemistry and molecular biology of ascorbic acid biosybthesis. Subcellular Biochemistry 1996;25:17.
47. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408-12.
48. Sterne 2001 Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. Journal of Clinical Epidemiology 2001;54:1046-1055.
49. WHO 1980 WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. Geneva. WHO, 1980.
50. WHO 1985 WHO Expert Committee on Diabetes Mellitus. World Health Organization, 1985. Technical Report Series 727.
51. WHO 1998 Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.